With the pricing ball in Gilead’s court, ICER offers some parameters on how it can be played — analyst sees at least '$1B in theory'
When asked directly on Gilead’s recent earnings call whether the company expects to profit from remdesivir — the only antiviral to have generated positive clinical data on a randomized, placebo-controlled trial and earned Anthony Fauci’s endorsement as a standard-of-care — Daniel O’Day was careful not to commit.
“(T)here is no guide book out there, there is no rule book out there,” the CEO said, pledging only to be “very thoughtful” about providing access.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.